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Abstract
Background: Cost-effectiveness analysis has been recognized as an important tool to determine the efficiency of
healthcare interventions and services. There is a need for evaluating the reporting of methods and results of cost-
effectiveness analyses and establishing their validity. We describe and examine reporting characteristics of methods
and results of cost-effectiveness analyses conducted in Spain during more than two decades.
Methods: A methodological systematic review was conducted with the information obtained through an updated
literature review in PubMed and complementary databases (e.g. Scopus, ISI Web of Science, National Health Service
Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA) databases from Centre for
Reviews and Dissemination (CRD), Índice Médico Español (IME) Índice Bibliográfico Español en Ciencias de la Salud
(IBECS)). We identified cost-effectiveness analyses conducted in Spain that used quality-adjusted life years (QALYs)
as outcome measures (period 1989–December 2014). Two reviewers independently extracted the data from each
paper. The data were analysed descriptively.
Results: In total, 223 studies were included. Very few studies (10; 4.5 %) reported working from a protocol. Most
studies (200; 89.7 %) were simulation models and included a median of 1000 patients. Only 105 (47.1 %) studies
presented an adequate description of the characteristics of the target population. Most study interventions were
categorized as therapeutic (189; 84.8 %) and nearly half (111; 49.8 %) considered an active alternative as the
comparator. Effectiveness of data was derived from a single study in 87 (39.0 %) reports, and only few (40; 17.9 %) used
evidence synthesis-based estimates. Few studies (42; 18.8 %) reported a full description of methods for QALY
calculation. The majority of the studies (147; 65.9 %) reported that the study intervention produced “more costs and
more QALYs” than the comparator. Most studies (200; 89.7 %) reported favourable conclusions. Main funding source
was the private for-profit sector (135; 60.5 %). Conflicts of interest were not disclosed in 88 (39.5 %) studies.
Conclusions: This methodological review reflects that reporting of several important aspects of methods and results
are frequently missing in published cost-effectiveness analyses. Without full and transparent reporting of how studies
were designed and conducted, it is difficult to assess the validity of study findings and conclusions.
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Background
Cost-effectiveness analysis has been recognized as an
important tool to assist clinicians, scientists and pol-
icymakers in determining the efficiency of healthcare
interventions, guiding societal decision-making on
the financing of healthcare services and establishing
research priorities. Given that the information pro-
vided by cost-effectiveness analysis has the potential
to impact population health and health services,
there is a need for evaluating the reporting of
methods and results of cost-effectiveness analyses
and establishing their validity to inform policy-
making [1–4].
Diverse approaches to synthesize evidence have been
considered in biomedical research [5–8], including eco-
nomic evaluations of healthcare interventions [9–16]. At
the same time, decision-making in health care requires
an understanding of the state of economic evaluation at
a national level, where the completeness of the reporting
is generally less well understood but where specific pri-
orities are often set. As a way of understanding the ma-
turity and growth of the field, several smaller studies
have examined a limited set of reporting characteristics
of cost-effectiveness analyses published in Spain [17–20].
Spain was a pioneer in proposing the standardization
and reporting of methodology applicable to cost-
effectiveness analysis [21, 22]. However, the institutional
and regulatory framework has so far not helped the ap-
plication of the methodology to the public health deci-
sions. The central government of Spain is the main
decision-maker in pricing and reimbursement related to
new medicines and healthcare technologies, although
with a high decentralization of health jurisdictions in
several regional health services, but traditionally, there
have been no national requirements related to the cost-
effectiveness for making coverage decisions.
We present herein a case study about reporting prac-
tices of economic evaluations of healthcare interventions
in one Western European country: Spain. Specifically,
this study expands upon previous research [23, 24] to
comprehensively describe and examine reporting charac-
teristics of methods and results of cost-effectiveness ana-
lyses conducted in Spain during more than two decades.
Methods
This methodological systematic review has been re-
ported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement [25] (see Additional file 1: Table S3). A
brief protocol was developed prior to the initiation of
this review. It can be acquired by request from the
corresponding authors. We did not register the proto-
col with PROSPERO given that the register does not
accept methodological reviews.
Literature search
The results from a previous review that examined col-
laborative patterns of scientific production in a cohort of
cost-effectiveness analyses conducted in Spain within the
period 1989–2011 [23] were updated with the studies
published until December 2014 and subsequently ana-
lysed. A systematic search was performed in PubMed/
MEDLINE and other databases such as Scopus, ISI Web
of Science, National Health Service Economic Evaluation
Database (NHS EED) and Health Technology Assess-
ment (HTA) databases of the Centre for Reviews and
Dissemination (CRD) at the University of York, UK, as
well as Índice Médico Español (IME) and Índice Biblio-
gráfico Español en Ciencias de la Salud (IBECS). The
search included a broad range of terms related to eco-
nomic evaluations of healthcare interventions, cost-
effectiveness analyses and the geographical area “Spain”.
For the section of geographical area, the search was
based on a previously validated filter by Valderas [26] to
minimize bias regarding the indexing of geographical
items. This filter is constructed around three comple-
mentary approaches: (a) the term “Spain” and its vari-
ants in various languages; (b) related mainly to region
and province place names and (c) acronyms for regional
health services. PubMed/MEDLINE and the above men-
tioned complementary databases were searched from
January 1, 2011 to December 31, 2014; the PubMed/
MEDLINE search strategy is provided in an online sup-
plement to this review (see Additional file 1: Table S1).
Furthermore, manual searches were made for publicly
available reports from the Health Technology Agencies
and publications in specialized Spanish journals.
Inclusion criteria and study selection
Our selection of studies was based on cost-effectiveness
analyses of healthcare interventions that used quality-
adjusted life years (QALYs) as outcome measure (see
Table 1 for terminology). In the health economic
Table 1 Terminology
Cost-effectiveness analysis is a specific form of economic evaluation
comparing two or more alternative programmes by measuring costs
and consequences. Consequences are measured in natural units
(e.g. life years gained or cases averted).
Cost-utility analysis is a variant of cost-effectiveness analysis, where
consequences are measured in terms of summary measures of
population health such as quality-adjusted life years.
Cost-effectiveness acceptability curve is a graphical representation of
the cost-effectiveness comparison between two interventions and plots
the probability that one intervention is more cost-effective than other,
as a function of the willingness-to-pay threshold for one additional unit
of benefits.
Incremental cost-effectiveness ratio (ICER) is the ratio of the change
in costs of an intervention (compared to the alternative) to the change
in effects of the intervention.
Quality-adjusted life years (QALYs) are a measure that combines
length of life and quality of life in a single outcome.
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literature, this type of studies is sometimes known as
“cost-utility analyses”. We selected this type of cost-
effectiveness analyses because many scientists and pol-
icymakers have recommended the QALY framework as
the standard reference for cost-effectiveness [27]. Studies
had to be undertaken in the Spanish population. Review
studies, editorials, and abstracts of congresses were ex-
cluded. If an article was found repeated in several publi-
cations, that published earlier (e.g. when there are two
or more articles of the same study) and/or published in
a journal with higher impact factor (e.g. when there ex-
ists a study published in both health technology assess-
ment report and journal manuscript) was included.
All citations of potential relevance identified from the
literature search were screened by one reviewer. Two re-
viewers reviewed all potentially relevant articles in full
text. Final inclusion was confirmed if both reviewers felt
the study was directly relevant to the objectives of this
methodological review. Planned involvement of a third
party to deal with unresolved discrepancies was not
required.
Data collection
Two reviewers (with expertise in health economics and
evidence synthesis) extracted data from each retrieved
paper independently. Data were collected using a self-
developed item data collection form designed to assess
reporting details of the studies. The process of data ex-
traction was piloted in 20 records. A final data extrac-
tion form was then agreed. To enable description of the
characteristics and the quality of reporting of cost-
effectiveness analyses in each report, we gathered the
following information from all studies: year and journal
of publication, impact factor (according to 2014 Journal
Citation Report), country of first author, mention of a
protocol, study objective, study design (e.g. randomized
trial, observational study, simulation model), interven-
tion targeted (e.g. prevention, diagnosis/prognosis, treat-
ment, rehabilitation), type of comparators (e.g. active
alternative, do nothing or placebo, usual care), perspec-
tive of analysis (in terms of which costs are considered,
e.g. society, national healthcare system, hospital, others),
type of costs (e.g. direct or indirect) and sources of in-
formation, the main cause of disease to which the inter-
vention or health programme was addressed, description
of population characteristics, time horizon, sources of
clinical effectiveness (e.g. based on a single study or
based on systematic reviews and meta-analyses), full de-
scription of methods for QALY calculation, discussion of
assumptions and validation of models (if applicable), dis-
count rates for costs and outcomes, results for the pri-
mary outcome in the base case scenario (e.g. “more
costs, more QALYs”, “less costs, more QALYs”, “less
costs, comparable QALYs”), incremental analyses
including incremental cost-effectiveness ratios (ICERs),
uncertainty measures (e.g. confidence intervals, accept-
ability curves), sensitivity analyses, limitations of study,
comparison of results with those of other studies, hypo-
thetical willingness-to-pay threshold and study conclu-
sions. Conclusions reported in the published article were
defined as follows: favourable if the intervention was
clearly claimed to be the preferred choice (e.g. cited as
“cost-effective”, “reduced costs”, “produced cost savings”,
“an affordable option”, “value for money”); unfavourable
if the final comments were negative (e.g. the interven-
tion is “unlikely to be cost-effective”, “produced higher
costs”, “is economically unattractive” or “exceeded con-
ventional thresholds of willingness to pay”); and neutral
or uncertain when the intervention of interest did not
surpass the comparator and/or when some uncertainty
was expressed in the conclusions. Disclosures of funding
source, conflicts of interest and authors’ contributions
were also evaluated.
Statistical analysis
A descriptive analysis was performed using frequency
and percentage counts. All calculations were performed
using Stata (Version 13, StataCorp LP, College Station,
TX, USA).
Results
Search
The flow diagram in Additional file 1: Figure S1 presents
the process of study selection.
Eight out of 131 identified studies from the cohort of
cost-effectiveness analysis conducted within the period
1989–2011 [23] were excluded for not meeting the de-
fined criteria. Our updated search identified 2014 re-
cords. Initial screening excluded 1914 records. The
remaining 100 full-text articles were assessed for add-
itional scrutiny, of which 21 where ineligible. Comple-
mentary searches through other sources (e.g. publicly
available reports from the Health Technology Agencies
and publications in specialized Spanish journals) identi-
fied 21 additional studies and were added to the previ-
ously identified, obtaining a total sample of 223 studies
(see Additional file 1: Table S2).
General characteristics
The 223 studies were published in 98 journals (206;
92.4 %) or assessment reports by the health technology
assessment agencies (17; 7.6 %). The majority of the
journals published only one cost-effectiveness analysis
although 15 journals each published four or more stud-
ies (Table 2). Most studies were published in journals
with impact factors ≤5.0 and only four studies were pub-
lished in journals with impact factor >10. The number
of studies increased exponentially over the study period
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(Additional file 1: Figure S2), with nearly half of the
cost-effectiveness analyses published during 2011–2014
(110; 49.3 %). More than half (127; 57.0 %) of the reports
were written in English. The studies included a median
of six authors although 44 (19.7 %) were authored by
eight or more authors and only 3 (1.3 %) reports were
single authored. The majority of the interventions were
classified as treatments (189; 84.8 %)—of which more
than 75 % (143/189) were pharmaceuticals. Cardiovascu-
lar diseases (47; 21.1 %) and malignant neoplasms (36;
16.1 %) were the disease conditions most commonly
studied.
Reporting characteristics of methods and results
Table 3 provides a summary of the descriptive and
reporting characteristics of the included studies. The
majority of the study reports used the specific terms
“cost-effectiveness” or “cost-utility analysis” in the title
(181; 81.2 %) and presented clearly the study question
(187; 83.9 %). However, only 10 studies (4.5 %) reported
working from a protocol—of which 7 were randomized
controlled trials, 2 were simulation models and 1 was an
observational study.
Of the identified studies, 200 (89.7 %) were model-based
being Markov models as the most frequently reported
(135; 60.5 %). A minimal number of non-model-based
studies were randomized controlled trials (10; 4.5 %).
Overall, most of the analyses were conducted in the
adult population (170; 76.2 %) but only 105 (47.1 %) pre-
sented an adequate description of the characteristics of
the base case population or identified the indication
clearly. The studies reporting the sample size (127; 57.0 %)
included a median of 1000 patients (25th percentile = 301;
75th percentile = 10000), although this number varied
considerably by the type of the study (e.g. clinical trials,
median = 115 patients; observational studies, median =
200 patients; and simulation models, median = 1000 pa-
tients). Most of the studies included an adequate descrip-
tion of the interventions and comparators (184; 82.5 %).
Nearly half (111; 49.8 %) of the studies considered an ac-
tive alternative as the comparator (e.g. drug, device, pro-
cedure, programme), 73 (32.7 %) used usual care and 39
(17.5 %) placebos or “do nothing”. The study perspective
was clearly stated in most of the analyses (207; 92.8 %).
The national healthcare system perspective was the most
commonly used (156; 70.0 %).
The time horizon was clearly reported in the majority
of studies (218; 97.8 %). Overall, 174 studies (78.0 %)
used a time horizon greater than 1 year.
Most studies (178; 79.8 %) reported on the diagram of
modelling or flow of patients (e.g. in the case of random-
ized controlled trials and observational studies). Most
studies (172; 77.1 %) reported on the assumptions
adopted for the analyses. Regarding the simulation and
Table 2 Characteristics of included cost-effectiveness analyses
(n = 223)
Characteristic Number Percent
Journals publishing
1 paper 60 61.2
2 papers 17 17.3
3 papers 6 6.1
4 papers or more 15 15.3
Papers by source
Journal articles 206 92.4
Health technology assessment reports 17 7.6
Papers by journal impact factor (JCR 2014)
None 88 39.5
0.1–2.0 61 27.3
2.1–5.0 58 26.0
5.1–10.0 12 5.4
>10.0 4 1.8
Papers by language of publication
English 127 57.0
Spanish 96 43.0
Number of authors per paper
1 3 1.3
2–3 33 14.8
4–7 143 64.8
≥8 44 19.7
Country of first author
Spain 183 82.1
UK 8 3.6
USA 7 3.1
Italy 5 2.2
The Netherlands 4 1.8
Sweden 4 1.8
Other 12 5.4
Focus of interventions
Prevention 18 8.1
Diagnosis/prognosis 15 6.7
Treatment 189 84.8
Rehabilitation 1 0.4
Disease conditions
Cardiovascular diseases 47 21.1
Malignant neoplasms 36 16.1
Infectious diseases 31 13.9
Neurological and mental disorders 30 13.4
Musculoskeletal disorders 20 9.0
Other conditions 59 26.5
JCR Journal Citation Report 2014
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Table 3 Descriptive and reporting characteristics of included cost-effectiveness analyses (n = 223)
Category Characteristic Number Percent
Title Identification
Specific terms “cost-effectiveness” or “cost-utility analysis” in title 181 81.2
Objective Study question
Clear presentation of study question and its relevance for decision-making 187 83.9
Methods Protocol
Existence of study protocol (or a priori established methods) 10 4.5
Type of study
Model based 200 89.7
Deterministic decision-tree model 29 13.0
Markov model 135 60.5
Discrete event simulation 11 4.9
Other (or unclear) 25 11.2
Non-model based 23 10.3
Observational (non-interventional) study 13 5.8
Randomized controlled trial 10 4.5
Population
Number of participants included (or simulated) 127 57.0
Adequate description of characteristics of the base case population 105 47.1
Adults 170 76.2
Children and adolescents 11 4.9
Newborn and infants (less than 1 year) 8 3.5
Overall population 4 1.8
Not reported 30 13.5
Type of interventions
Pharmaceuticals 143 64.1
Device/procedure 28 12.6
Screening 16 7.2
Surgery 12 5.4
Educational/behavioural 8 3.6
Other 16 7.2
Type of comparators
Active alternative 111 49.8
Usual care 73 32.7
Placebo or do nothing 39 17.5
Adequate description of interventions and comparators 184 82.5
Study perspective clearly stated 207 92.8
National Health System only 156 70.0
National Health System and societal 25 11.2
Societal only 17 7.6
Hospital 9 4.0
Time horizon reported 218 97.8
Short term 44 19.7
Long term (>1 year and lifetime) 174 78.0
Diagram of model or patients/events pathway reported 178 79.8
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Table 3 Descriptive and reporting characteristics of included cost-effectiveness analyses (n = 223) (Continued)
Assumptions discussed 172 77.1
Model validation discussed (when applicable) 88 44.0
Reasons for the specific model used (when applicable) 91 45.5
Measurement of effectivenessa
Based on a single study 87 39.0
Based on evidence synthesis (e.g. systematic review and/or meta-analysis) 40 17.9
Full description of QALY calculation 42 18.8
Harms were considered 129 57.8
Cost and resources information
Source of valuation for all cost items reported 216 96.9
Quantity of resources 107 48.0
Year of monetary units 195 87.4
Costing
Direct costs only 182 81.6
Direct and indirect costs 41 18.4
Discount rate for costs and QALYs 161 72.2
Results Net costs reported 197 88.3
Net benefits reported 192 86.1
Incremental cost-effectiveness ratio (ICER) reported 207 92.8
Confidence intervals (e.g. 95 % CI) 27 12.1
Cost-effectiveness plane 99 44.4
Acceptability curves 92 41.3
Sensitivity analysis reported 201 90.1
For costs 170 76.2
For estimates of effectiveness 158 70.9
For utility weights 95 42.6
For discount rates 82 36.8
Type of sensitivity analysis
Deterministic univariate 85 38.1
Deterministic multivariate 6 2.7
Probabilistic 110 49.3
Results for the primary outcome in the base case scenario
More costs, more QALYs 147 65.9
Less costs, more QALYs 63 28.3
Less costs, comparable QALYs 5 2.2
More costs, comparable QALYs 4 1.8
Less costs, less QALYs 2 0.9
Comparable costs, more QALYs 2 0.9
Discussion Limitations of study discussed 197 88.3
Results compared with those of other economic evaluations 165 74.0
Hypothetical willingness-to-pay (WTP) threshold reported
<30,000 €/QALY 4 1.8
30,000 €/QALY 126 56.5
>30,000 €/QALY–≤50,000 €/QALY 36 16.1
>50,000 €/QALY 7 3.1
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modelling-based studies, nearly half reported reasons for
the specific model used (91/200; 45.5 %) and/or provided
some information on the model validation (88/200;
44.0 %) such as previous publication in other settings.
Effectiveness of data was derived from a single study
in 87 (39.0 %) analyses. Only 40 (17.9 %) used evidence
synthesis-based estimates (e.g. systematic reviews and
meta-analyses).
The methods that were reported for calculating QALYs
are detailed in Table 4. Overall, a small number of the
studies (42; 18.8 %) reported a full description of
methods for QALY calculation. About half of the studies
(109; 48.9 %) reported information on the health-state
classification system, of which the EuroQoL-5D was the
instrument most commonly reported (82; 36.8 %). Half
of the studies (115; 51.6 %) provided the source of the
preferences. Most frequently, the patients and their care-
givers (103; 46.2 %) were the source. Only a small num-
ber of the studies (43; 19.3 %) provided information on
the measurement technique used for valuing health
Table 3 Descriptive and reporting characteristics of included cost-effectiveness analyses (n = 223) (Continued)
Unclear or not reported 50 22.4
Study conclusions
Favourable 200 89.7
Unfavourable 12 5.4
Neutral/unclear 11 4.9
Other Disclosed funding sources 169 75.8
Private/for profit 135 60.5
Public 38 17.0
None/not reported 49 22.0
Mixed 1 0.4
Disclosed conflicts of interest 135 60.5
With conflicts of interest 94 42.1
With no conflicts of interest 41 18.4
Disclosed authors’ contribution 46 20.6
aMeasurement of effectiveness only relates to effect estimates. The epidemiology of disease and/or transition probabilities were not necessarily based on a
systematic review and meta-analysis
Table 4 Descriptive and reporting characteristics of methods used in calculating QALYs
Category Characteristic Number Percent
Health-state classification system EuroQoL-5D 82 36.8
SF-36 6 2.7
Rosser scale 6 2.7
Health Utility Index (HUI) 2 0.9
Other 13 5.8
Not reported 114 51.1
Source of preferences Patient/caregiver 103 46.2
Community 10 4.5
Clinician/author 2 0.9
Not reported 108 48.4
Measurement technique used for valuing health state Time tradeoff (TTO) 22 9.9
Visual analogue scale (VAS) 12 5.4
Standard gamble (SG) 5 2.2
Tariffs for classification 4 1.8
Not reported 182 81.6
Country/region of reference for utility weights National/local population (e.g. Spain) 50 22.4
Citation of the international literature 143 64.1
Not reported 30 13.5
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states. The time tradeoff (22; 9.9 %) was the most com-
monly used technique. The majority of the studies used
the published international literature for data on utility
weights (143; 64.1 %) and only 50 studies (22.4 %) re-
ported country-specific utility weights for Spain.
Half of the studies (129; 57.8 %) reported on some as-
pect of harms.
Ninety-seven percent (216) of the studies identified
sources of valuation for costing items, and 87.4 % (195) in-
dicated the year of currency. Overall, 107 (48.0 %) studies
described quantity of resources. Eighteen percent (41) of
studies included indirect costs. Seventy-two percent (161)
of studies discounted both costs and QALYs. Of the stud-
ies with a time horizon greater than 1 year (Table 5), the
most commonly used was a 3 % discount rate.
In terms of results (Table 3), most of the studies (207;
92.8 %) reported ICERs (median = 16,908 €; 25th per-
centile = 8,998 €; 75th percentile = 38,000 €). However,
few studies (27; 12.1 %) described point estimates to-
gether with an associated confidence interval. Nearly
half of the studies (99; 44.4 %) reported the cost-
effectiveness plane. Similarly, less than half of the studies
(92; 41.3 %) reported a willingness-to-pay curve (“cost-
effectiveness acceptability curve”) to contrast the results
of the analyses against an arbitrary efficiency threshold.
Overall, 90.1 % (201) of studies reported sensitivity ana-
lyses. About half of the studies (110; 49.3 %) conducted
a probabilistic sensitivity analysis. The majority of the
studies (147; 65.9 %) reported that the study intervention
produced “more costs and more QALYs” than the alter-
native comparator for the primary outcome of the base
case scenario. Sixty-three (28.3 %) studies reported that
the intervention was a dominant strategy, that means
that the study intervention was “more effective and less
costly” than the alternative.
Overall, the vast majority of the studies (197; 88.3 %)
discussed limitations of the analyses. Most studies (165;
74.0 %) compared their results with those of previous
economic analyses. About half of the studies (126;
56.5 %) mentioned a hypothetical willingness-to-pay
threshold of 30,000 €/QALY. The majority of studies
(200; 89.7 %) reported favourable conclusions for the
primary outcomes. Only a minority (12; 5.4 %) of pub-
lished cost-effectiveness analyses reported unfavourable
conclusions. About three fourths (169; 75.8 %) reported
funding sources, being the private for-profit sector the
main source (135; 60.5 %). Conflicts of interest were not
disclosed in 88 (39.5 %) studies. Authors’ contributions
were only reported in 46 (20.6 %) studies (Table 3).
Discussion
In this methodological systematic review, we identified
223 reports of cost-effectiveness analyses conducted in
Spain over the period 1989–2014. Overall, the studies
covered a wide range of disease conditions but predom-
inantly addressed questions about the efficiency of thera-
peutic interventions. Our review, as well as other
previously published reviews [11–14], showed that the
quality of reporting of cost-effectiveness analyses varies
widely and, in many cases, essential components of
reporting methods and results were missing in published
reports, such as the use of study protocols, the adequate
description of patient characteristics, the measurement
of clinical effectiveness using a systematic review process
or the adequate description of QALY calculation.
Our study suggests the need for improvement in sev-
eral aspects of published cost-effectiveness analyses. An
important element in assessing research conduct and
reporting is the study protocol. As showed in this re-
view, only 4 % of studies reported working from a proto-
col. Study protocols play an essential role in planning,
conduct, interpretation, and external review of primary
studies, but also in evidence synthesis of primary re-
search. For example, the preparation and publication of
a well-written protocol may reduce arbitrariness in
decision-making when extracting and using data from
primary research for populating health economic
models. When clearly reported protocols are made avail-
able, they enable readers to identify deviations from
planned methods and whether they bias the interpret-
ation of results and conclusions [28, 29]. International
registries (such as ClinicalTrials.gov for clinical trials
and PROSPERO for systematic reviews and meta-
analysis) are now a reality. Similarly, in recent years,
reporting guidelines for protocols have been endorsed
and implemented (e.g. Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) for proto-
cols of clinical trials [28] and PRISMA for protocols
(PRISMA-P) of systematic reviews [29]). However, in
view of our results, this revolution has not occurred yet
in the field of cost-effectiveness research and, thus, could
warrant further pragmatic action.
Table 5 Discount rates used in included cost-effectiveness
analyses
Costs QALYs
Discount rate (%) Number Percent Number Percent
1.5 – – 3 1.7
2 1 0.6 1 0.6
3 107 61.5 109 62.6
3.5 31 17.8 31 17.8
4 1 0.6 1 0.6
5 5 2.9 4 2.3
6 13 7.5 11 4.9
Totala 174 100.0 174 100.0
aIncludes cost-effectiveness analyses that investigated costs or QALYs over
time horizons of more than 1 year
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Many cost-effectiveness analyses (about 53 %) did not re-
port detailed information on baseline clinical characteristics
(e.g. eligibility and exclusion criteria of participants, the se-
verity of disease, the stage in the natural history of the dis-
ease, comorbidities). Inadequate reporting of the
characteristics of the target population is a far greater bar-
rier to the assessment of the study’s generalizability (applic-
ability) and relevance to decision-making [30–32]. It is
possible that this poor reporting reflects a major problem
in secondary publications, such as many cost-effectiveness
analyses using simulation models. Given that a clear under-
standing of these elements is required to judge to whom
the results of a study apply (as the Consolidated Standards
of Reporting Trials (CONSORT) [31, 32] statement under-
lines for randomized controlled trials), this information
should also be provided in the report of cost-effectiveness
analyses (e.g. in main text or in online supplement when
allowed).
The vast majority (about 90 %) of published cost-
effectiveness analyses used decision modelling as the
main methodology. Decision modelling is considered a
methodological approach of evidence synthesis that
reaches beyond the scope of systematic reviews and
meta-analyses. It is essential for cost-effectiveness re-
search to use all relevant evidence on the effectiveness
of interventions under evaluation. Rarely will all relevant
evidence come from a single study, and typically, it will
have to be drawn from several clinical studies [33]. A
disappointing result of this review is that few published
studies reported the use of a systematic review process
for the measurement of clinical effectiveness. While sys-
tematic reviews and meta-analyses are considered to be
the gold standard in knowledge synthesis, only 18 % of
published cost-effectiveness analyses used evidence
synthesis-based estimates of effect. Instead, 43 % of the
studies make arbitrary decisions about what studies to
use to inform effectiveness data, whereas 39 % of the
studies reported that the effectiveness data derived from
a single study (generally, without a clear description of
why the single study was a sufficient source of all rele-
vant clinical evidence). The use of QALYs is recognized
as the main valuation technique to measure health out-
comes in cost-effectiveness analyses. However, in our re-
view, it was also troubling that few studies (19 %)
reported a full description of methods for QALY estima-
tion, thus potentially impairing confidence in the results
and conclusions. Future studies should be transparent in
reporting these important aspects.
Strong evidence of publication bias and other potential
sources of bias have been reported in biomedical re-
search [34–38]. For example, randomized controlled tri-
als with “positive” findings are published more often,
and more quickly, than trials with “negative” findings
[37]. Similarly, empirical studies have detected that most
published cost-effectiveness analyses report favourable
findings [38]. In our review, very few published studies
(about 10 %) reported unfavourable or neutral conclu-
sions. Although it is somewhat premature to comment
on this finding, this could be indicative of potential
biases, such as publication bias or even potential screen-
ing a priori that may have been performed by the pro-
ducers of studies, which would make that cost-
effectiveness analyses would have been only conducted
in cases where a “positive” result was expected. In our
opinion, this issue requires further investigation.
Several reporting guidelines are available and endorsed
for many types of biomedical research [25, 28, 29, 31,
39] but also for cost-effectiveness analyses [40–46]. Such
tools promote the consistent reporting of a minimal set
of information for scientists and researchers reporting
studies and the editors and peer reviewers assessing
them for publication. Endorsement of reporting guide-
lines by journals for randomized controlled trials [47]
and systematic reviews [48] has been shown to improve
the quality of reporting. The incorporation of reporting
guidelines within the peer-review process could poten-
tially contribute to improvements in the quality of re-
ports of cost-effectiveness analyses. On this regard, the
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) statement [40] has been proposed
as an attempt to consolidate and update previous efforts
[41–46] into a single useful reporting guideline for cost-
effectiveness research. Authors, peer reviewers and edi-
tors can promote reporting guideline endorsement and
implementation as an important way to improve trans-
parency and completeness of what they published, redu-
cing waste in reporting research and increasing value
[49, 50] of cost-effectiveness research.
Our study has several limitations. First, although the
review has been drawn from an exhaustive review of ori-
ginal reports of cost-effectiveness analyses, it is possible
that the search missed some articles with relevant ele-
ments or that some studies conducted may not have
been published. In addition, for some reports repeated
in several publications, our approach was the inclusion
of those published in a journal with higher impact factor
and/or published earlier [23, 24]. Thus, the decision to
use report level instead treating the study as the unit of
analysis may have limited the collection of all the report-
ing characteristics from multiple reports of the same
study (where there exist). Second, we restricted our ana-
lysis to cost-effectiveness analyses that used QALYs as
health outcome measure (namely, cost-utility analyses).
In a previous descriptive analysis of economic evalua-
tions conducted in Spain [24], only about 15 % are cost-
utility analyses. It would be interesting to explore
whether other forms of economic evaluations using al-
ternative outcome measures results in similar reporting
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patterns. Third, we relied upon the expertise and experi-
ence of our authorship team and on existing documents
[16, 22] to identify core items related to the conduct and
reporting that we would like to see (in the position of
potential readers) in any published cost-effectiveness
analysis. Given the dynamic nature of research, some op-
portunities for future research and development could
be the impact assessment of a specific reporting guide-
line (such as the CHEERS statement [40]) and/or local
recommendations on the reporting quality of published
studies [51]. Fourth, the extent of the reporting of cost-
effectiveness analyses was limited to the information
publicly available in the corresponding report (and on-
line data supplements when available). There were no
further inquiries or attempts to verify the data sources
and tools used in the studies and only information about
reporting characteristics was taken into account in the
review, without considering other possible sources (e.g.
contacting authors and/or their sponsors).
Conclusions
We presented a national case study for more
generalizable discussions about quality and transparency
issues of reporting cost-effectiveness analyses, likely to
be of interest to authors, peer reviewers and editors—but
also research funders and regulators—both within and
beyond Spain. Based on the existing evidence, several
deficiencies in the reporting of important aspects of
methods and results are apparent in published cost-
effectiveness analyses.
Our study raises challenges for increasing value and
reducing waste in cost-effectiveness research. Without
full and transparent reporting of how studies were de-
signed and conducted, it is difficult to assess validity of
study findings and conclusions of published studies. This
review also reinforces the need to improve mechanisms
of peer review and publication process of cost-
effectiveness research.
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